Keywords
Infectious diseases
Challenges
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To identify the challenges of antimicrobial resistance in the management of infectious diseases and to list strategies for controlling this resistance. Methods: This is an integrative review carried out through searches in the PubMED, CAPES Journal and BVS databases, using the descriptors: “Bacteria”; “Communicable diseases”; “Bacterial drug resistance”; “Bacterial infections”; “Treatment outcome” and obtaining the search truncation: (“Drug Resistance, Microbial” OR “Bacteria”) AND (“Infectious diseases” OR “Bacterial Infections”) AND (Treatment Outcome). Eighteen articles published in the last 2 years and available in full were included, and those that did not meet the research objective were excluded. Results: The main challenges in antimicrobial resistance in infectious diseases are: the need for new research and effective antimicrobials, inappropriate prescription and the proliferation of resistant bacteria in hospitals. The development of new treatments faces economic obstacles and lack of standardization, while inappropriate medical prescribing exacerbates the problem. In addition, transmission of resistant bacteria is intensified by inadequate hygiene practices and use of PPE, in addition to the difficulty in isolating infected patients. Conclusion: It is concluded that, despite advances, challenges persist in the management of antimicrobial resistance, requiring research focused on new antibiotics, judicious prescribing, and education on the correct use of antimicrobials.
References
ALTARAWNEH H, et al. Synergistic bactericidal activity of a novel dual β-lactam combination against methicillin-resistant Staphylococcus aureus. The journal of antimicrobial chemotherapy, 2024; 79(7): 1677–1682.
ARNS B, et al. A randomized, open-label, non-inferiority clinical trial assessing 7 versus 14 days of antimicrobial therapy for severe multidrug-resistant gram-negative bacterial infections: The OPTIMISE trial protocol. Infectious diseases and therapy, 2024; 13(1): 237–250.
BADGER-EMEKA L, et al. Incidence of drug-resistant hospital-associated gram-negative bacterial infections, the accompanying risk factors, and clinical outcomes with treatment. Antibiotics (Basel, Switzerland), 2023; 12(9).
CORCIONE S, et al. Cefiderocol use in Gram negative infections with limited therapeutic options: Is combination therapy the key? Journal of infection and public health, 2022; 15(9): 975–979.
DING H, et al. Incidence of drug-resistant pathogens in community-acquired pneumonia at a safety net hospital. Microbiology spectrum, 2024; 0079224.
DUNNE MW, et al. Impact of empirical antibiotic therapy on outcomes of outpatient urinary tract infection due to nonsusceptible Enterobacterales. Microbiology spectrum, 2022; 10(1): 0235921.
GORANOVA M, et al. Evolutionary optimisation of antibiotic dosing regimens for bacteria with different levels of resistance. Artificial intelligence in medicine, 2022; 133(102405): 102405.
GRANATA G e CICALINI S. The evolving challenge of appropriate antibiotics use in hospitalized COVID-19 patients: A systematic literature review. Antibiotics (Basel, Switzerland), 2024; 13(6): 545.
KANJ SS, et al. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections. International journal of antimicrobial agents, 2022; 60(3): 106633.
LI K, et al. Ceftazidime-avibactam combination therapy versus monotherapy for the treatment of carbapenem-resistant gram-negative bacterial infections: A retrospective observational study. Infection and drug resistance, 2024; 17: 1281–1289.
MAEDA M, et al. Efficacy of carbapenems versus alternative antimicrobials for treating complicated urinary tract infections caused by antimicrobial-resistant Gram-negative bacteria: protocol for a systematic review and meta-analysis. BMJ open, 2023; 13(4): 69166.
MO Y et al. Implications of reducing antibiotic treatment duration for antimicrobial resistance in hospital settings: A modelling study and meta-analysis. PLoS medicine, 2023; 20(6): 1004013.
ONALLAH H, et al. Compassionate use of bacteriophages for failed persistent infections during the first 5 years of the Israeli Phage Therapy Center. Open forum infectious diseases, 2023; 10(5): 221.
PARK KH, et al. Impact of multidrug resistance on outcomes in hematologic cancer patients with bacterial bloodstream infections. Scientific reports, 2024; 14(1): 15622.
PAUL M, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022; 28(4): 521–547.
PINA-VAZ C, et al. A multisite validation of a two hours antibiotic susceptibility flow cytometry assay directly from positive blood cultures. BMC microbiology, 2024; 24(1).
RAHMAN MN, et al. The use of probiotics and prebiotics in decolonizing pathogenic bacteria from the gut; a systematic review and meta-analysis of clinical outcomes. Gut microbes, 2024; 16(1): 2356279.
SUBAGDJA MFM, et al. Antibiotic resistance in COVID-19 with bacterial infection: Laboratory-based surveillance study at single tertiary hospital in Indonesia. Infection and drug resistance, 2022; 15: 5849–5856.
TANG PC, et al. Within-species variability of antibiotic interactions in Gram-negative bacteria. mBio, 2024; 15(3).
TANTALO LC, et al. Antimicrobial susceptibility of Treponema pallidum subspecies pallidum: an in-vitro study. The Lancet. Microbe, 2023; 4(12): 994–1004.
TAYLOR SL, et al. Preventing empirical antibiotic treatment failure in migrant populations: screening by infection risk, not ethnic background. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases, 2023; 134: 168–171.
VALLICELLI C, et al. Sepsis team organizational model to decrease mortality for intra-abdominal infections: Is antibiotic stewardship enough? Antibiotics (Basel, Switzerland), 2022; 11(11): 1460.
VAN DUIJN PJ, et al. The effects of antibiotic cycling and mixing on acquisition of antibiotic resistant bacteria in the ICU: A post-hoc individual patient analysis of a prospective cluster-randomized crossover study. PloS one, 2022; 17(5): 0265720.
WITZANY C, et al. Assessing the relative importance of bacterial resistance, persistence and hyper-mutation for antibiotic treatment failure, Proceedings. Biological sciences, 2022; 289(1986): 20221300.
ZHANG F, et al. Clinical outcomes and risk factors for mortality in recipients with carbapenem-resistant gram-negative bacilli infections after kidney transplantation treated with ceftazidime-avibactam: a retrospective study. Frontiers in cellular and infection microbiology, 2024; 14.
ZHOU Y, et al. Efficacy and safety of different polymyxin-containing regimens for the treatment of pneumonia caused by multidrug-resistant gram-negative bacteria: a systematic review and network meta-analysis. Critical care (London, England), 2024; 28(1).